Genmab, a premier biotech firm, witnessed a series of events significantly influencing its stock's trajectory. The company announces a partnership with Anthropic that targeted
faster drug development via AI tech. Genmab recorded an
earnings surge of 131% pushing the stock into a buy zone, creating positive momentum. It managed to score a
FDA Breakthrough for Rina-S. Furthermore, collaborations were instrumental in shaping the company's value, including a notable $8 billion acquisition of Merus that resulted in
delisting Merus shares from Nasdaq and the quick-to-react market led to a soaring of Genmab's stock by 65%. Also, the discontinuing of acasunlimab development resulted in a dip in stock price. Throughout the period, various agencies, including UBS, H.C. Wainwright, Truist, and Leerink Partners, showed confidence in Genmab's growth potential and raised the
stock price target. The sales of Darzalex drove
Gemab's robust demand and growth during Q3 of 2025 causing it to be undervalued. However, a deal involving restricted stock units and warrants issued to employees, which led to an increase in capital, caused a slight dip in the stock price.
Genmab Stocks News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sat, 10 Jan 2026 20:06:13 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor -2
